{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:09:38Z","timestamp":1778940578011,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bneo.2025.100123","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T12:46:22Z","timestamp":1748954782000},"page":"100123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML"],"prefix":"10.1016","volume":"2","author":[{"given":"Vinod A.","family":"Pullarkat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0473-6982","authenticated-orcid":false,"given":"Mark","family":"Levis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel N.","family":"Mannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-2041","authenticated-orcid":false,"given":"Stephen A.","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5848-6221","authenticated-orcid":false,"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0242-6449","authenticated-orcid":false,"given":"Tara L.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-0533","authenticated-orcid":false,"given":"Vijaya R.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4662-0083","authenticated-orcid":false,"given":"Thuva","family":"Vanniyasingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yana","family":"Lutska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald S.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1093-2189","authenticated-orcid":false,"given":"Harry P.","family":"Erba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bneo.2025.100123_bib1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2025.100123_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100123_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100123_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17746","article-title":"Updates on targeted therapies for acute myeloid leukaemia","volume":"196","author":"Kayser","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bneo.2025.100123_bib5","series-title":"VYXEOS\u00ae (daunorubincin and cytarabine) liposome for injection for intravenous use [prescribing information]","year":"2022"},{"key":"10.1016\/j.bneo.2025.100123_bib6","series-title":"VYXEOS\u00ae (daunorubicin and cytarabine liposome for injection) product monograph","year":"2023"},{"key":"10.1016\/j.bneo.2025.100123_bib7","series-title":"Vyxeos liposomal (44 mg\/100 mg powder for concentrate for solution for infusion) summary of product characteristics","year":"2024"},{"key":"10.1016\/j.bneo.2025.100123_bib8","series-title":"Vyxeos liposomal (44 mg\/100 mg powder for concentrate for solution for infusion) summary of product characteristics","year":"2024"},{"issue":"26","key":"10.1016\/j.bneo.2025.100123_bib9","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100123_bib10","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2025.100123_bib11","article-title":"In vitro cytotoxicity of CPX-351 plus venetoclax compared with hypomethylating agents or cytarabine plus venetoclax [abstract]","volume":"80","author":"Gupta","year":"2020","journal-title":"Cancer Res"},{"issue":"suppl 13","key":"10.1016\/j.bneo.2025.100123_bib12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1538-7445.AM2017-1087","article-title":"Abstract 1087: CPX-351 works synergistically in combination with FLT3 inhibitors against AML with FLT3-ITD","volume":"77","author":"Edwards","year":"2017","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.bneo.2025.100123_bib13","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100123_bib14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.bneo.2025.100123_bib15","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2025.100123_bib16","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"130","article-title":"Acute myeloid leukaemia and related precursor neoplasms","volume":"Vol. 2","author":"Arber","year":"2017"},{"issue":"25","key":"10.1016\/j.bneo.2025.100123_bib17","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bneo.2025.100123_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00280-019-03856-9","article-title":"A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias","volume":"84","author":"Lin","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100123_bib19","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"28","key":"10.1016\/j.bneo.2025.100123_bib20","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100123_bib21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia","volume":"29","author":"Feldman","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100123_bib22","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.leukres.2010.07.031","article-title":"Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases","volume":"35","author":"Noor","year":"2011","journal-title":"Leuk Res"},{"issue":"31","key":"10.1016\/j.bneo.2025.100123_bib23","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100123_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100123_bib25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bneo.2025.100123_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100123_bib27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/hematology.2019000006","article-title":"Minimal residual disease and stem cell transplantation outcomes","volume":"2019","author":"Cloos","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"24","key":"10.1016\/j.bneo.2025.100123_bib28","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1182\/bloodadvances.2024013687","article-title":"Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy","volume":"8","author":"Uy","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100123_bib29","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1182\/blood-2024-205977","article-title":"A phase 1 study of CPX-351 plus gilteritinib in relapsed or refractory FLT3-mutated acute myeloid leukemia","volume":"144","author":"Chan","year":"2024","journal-title":"Blood"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:06Z","timestamp":1778938626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950328025000585"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100123","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100123"}}